Frequencies of the CYP3A5*3 variant in renal transplant patients in Northern Portugal

被引：0
|
作者：
Lima, Carla [1 ]
Peixoto, Maria [1 ]
Dias, Manuel [1 ]
Alves, Helena [1 ]
机构：
[1] N Histocompatibil Ctr, Oporto, Portugal
来源：
TISSUE ANTIGENS | 2010年 / 75卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：589 / 590
页数：2
相关论文
共 50 条
  • [31] Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians
    E Gebeyehu
    E Engidawork
    A Bijnsdorp
    A Aminy
    U Diczfalusy
    E Aklillu
    The Pharmacogenomics Journal, 2011, 11 : 130 - 137
  • [32] Sirolimus oral clearance is significantly higher in CYP3A5*1 vs CYP3A5*3 de novo renal transplant recipients with no associated calcineurin inhibitor.
    Marquet, P
    Djebli, N
    Toupance, O
    Hoizey, G
    Rousseau, A
    Le Meur, Y
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 448 - 448
  • [33] Trans-eQTLs of the CYP3A4 and CYP3A5 associated with tacrolimus trough blood concentration in Chinese renal transplant patients
    Lu, Huijie
    Jiang, Haixia
    Yang, Siyao
    Li, Chengcheng
    Li, Chuanjiang
    Shao, Ruifan
    Zhang, Pai
    Wang, Daoyi
    Liu, Zhiwei
    Qi, Huana
    Cai, Yinuan
    Xu, Wenbin
    Bao, Xiaojie
    Wang, Hailan
    Li, Liang
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 145
  • [34] Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients
    Zhu, Wan
    Xue, Ling
    Peng, Hongwei
    Duan, Zhouping
    Zheng, Xuelian
    Cao, Duanwen
    Wen, Jinhua
    Wei, Xiaohua
    PHARMACOGENOMICS, 2018, 19 (13) : 1013 - 1025
  • [35] In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients
    de Jonge, H.
    de Loor, H.
    Verbeke, K.
    Vanrenterghem, Y.
    Kuypers, D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (03) : 366 - 375
  • [36] Effect of drug combination on tacrolimus target dose in renal transplant patients with different CYP3A5 genotypes
    Zhang, Shu-Fang
    Tang, Bo-Hao
    Wei, An-Hua
    Du, Yue
    Guan, Zi-Wan
    Li, Yan
    XENOBIOTICA, 2022, 52 (03) : 312 - 321
  • [37] A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
    Lee, Su-Jun
    van der Heiden, Ilse P.
    Goldstein, Joyce A.
    van Schaik, Ron H. N.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (01) : 67 - 71
  • [38] Analysis of CYP3A5*3 and CYP3A5*6 Gene Polymorphisms in Indian Chronic Myeloid Leukemia Patients
    Sailaja, K.
    Surekha, D.
    Rao, D. Nageswara
    Rao, D. Raghunadha
    Vishnupriya, S.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (03) : 781 - 784
  • [39] ASSOCIATION BETWEEN CYP3A5*3 AND PPARA GENE VARIANTS ON TACROLIMUS CONCENTRATIONS IN RENAL TRANSPLANT RECIPIENTS
    Lunde, Ingrid
    Midtvedt, Karsten
    Mohebi, Beata
    Dahl, Miriam
    Bergan, Stein
    Asberg, Anders
    Christensen, Hege
    Bremer, Sara
    TRANSPLANT INTERNATIONAL, 2013, 26 : 252 - 252
  • [40] CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients
    Le Meur, Yannick
    Djebli, Nassim
    Szelag, Jean-Christophe
    Hoizey, Guillaume
    Toupance, Olivier
    Rerolle, Jean Philippe
    Marquet, Pierre
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) : 51 - 60
12345